Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and tim-3 exhaustion markers

Clinical Cancer Research

Volumn 19, Issue 19, 2013, Pages 5351-5360

  Afanasiev, Olga K ^a,b   Yelistratova, Lola ^a   Miller, Natalie ^a,b   Nagase, Kotaro ^e   Paulson, Kelly ^a,b   Iyer, Jayasri G ^a   Ibrani, Dafina ^a   Koelle, David M ^a,b,c,d   Nghiem, Paul ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Department of Pathology ^*  (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; MESSENGER RNA; ONCOPROTEIN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TIM 3; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER INHIBITION; CELL ACTIVATION; CELL EXPANSION; CELL FUNCTION; CELL ISOLATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA FINGERPRINTING; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ESCAPE; TUMOR VOLUME;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BIOLOGICAL MARKERS; CARCINOMA, MERKEL CELL; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; MERKEL CELL POLYOMAVIRUS; ONCOGENE PROTEINS, VIRAL; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTE SUBSETS; TUMOR BURDEN;

EID: 84886419114     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0035     Document Type: Article

References (35)

1. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 2010;63:751-61.
2. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE, et al. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol (2009).
3. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005;89:1-4.
4. Moll R, L?owe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-47.
5. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Penas PF, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008;58:375-81.
6. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096-100.
7. Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, et al. Merkel cell polyomavirus-infected merkel cell carcinoma cells require expression of viral T antigens. J Virol 2010;84:7064-72.
8. Rodig SJ, Cheng J, Wardzala J, Dorosario A, Scanlon JJ, Laga AC, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 2012;122:4645-53.
9. Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011;29:1539-46.
10. Paulson KG, Iyer JG, Blom A, Warton EM, Sokil M, Yelistratova L, et al. Systemic immune suppression as a stage-independent predictor of diminished Merkel cell carcinoma-specific survival. J Invest Dermatol 2012;133:-642-6.
11. Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, Jing L, et al. Merkel cell polyomavirus-specific CD8+ and CD4+ T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res 2011;17:6671-80.
12. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
13. Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother 2012;61:1721-33.
14. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010;207:2187-94.
15. Ngiow SF, Von Scheidt B, Akiba H, Yagita H, Teng MWL, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011;71: 3540-51.
16. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66: 3381-5.
17. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104:3360-5.
18. Kr?onig H, Julia Falchner K, Odendahl M, Brackertz B, Conrad H, Muck D, et al. PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease. Int J Cancer 2012; 130:2327-36.
19. Shuda M, Arora R, Kwun HJ, Feng H, Sarid R, Fernández-Figueras M-T, et al. Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer 2009;125:1243-9.
20. Paulson KG, Carter JJ, Johnson LG, Cahill KW, Iyer JG, Schrama D, et al. Antibodies to Merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in Merkel cell carcinoma patients. Cancer Res 2010; 70:8388-97.
21. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients. J Exp Med 2010;207:2175-86.
22. Greenough TC, Campellone SC, Brody R, Jain S, Sanchez-Merino V, Somasundaran M, et al. Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage. PLoS ONE 2010;5: e12926.
23. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7.
24. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008;205:2763-79.
25. Wherry EJ. T cell exhaustion. Nat Immunol 2011;131:492-9.
26. McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, Allen TM, et al. Tim-3 expression on PD-1(+) HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010;120: 4546-57.
27. Jin H-T, Anderson AC, Tan WG, West EE, Ha S-J, Araki K, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010;107:14733-8.
28. Kaech SM, Wherry EJ, Ahmed R. Vaccines: effector and memory t-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002;2:251-62.
29. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116:1757-66.
30. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-77.
31. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-7.
32. Taube JM, Anders RA, Young GD, Xu H, Sharma R, Mcmiller TL, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra137.
33. Dowlatshahi M, Huang V, Gehad A, Jiang Y, Calarese A, Teague JE, et al. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T cell exhaustion in reducing T cell responses. J Invest Dermatol 2013;133:1879-89.
34. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
35. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry 2011;79A: 167-74.